phone Book Now
phone Book Now
Rockyview Health Centre, 1011 Glenmore Trail SW Building #1 Suite 423, Calgary, AB T2V 4R6, Canada
587-353-5061 Book Appointment
Mission
We are passionate about your eyes, and about building long-lasting relationships. Our goal is to ensure your eyes remain healthy throughout your life. We are all about service, love, kindness and a belief in strong community. Through our holistic approach to caring for you and our dedication to learning, we pioneer carefully researched new treatments, technology, and products to help ensure eye health.

Dr. Jessica Yang, OD is a proud Calgarian who brings hometown warmth and exceptional clinical training to her patients at Eyedeology. She earned her Bachelor of Science in Biology from the University of Calgary before completing her Doctor of Optometry degree at the University of Waterloo School of Optometry and Vision Science.
During her final year, Dr. Jessica completed an ocular disease externship at the Veterans Affairs Hospital in Muskogee, Oklahoma, where she gained advanced experience diagnosing and managing glaucoma, macular degeneration, dry eye disease, and diabetic retinopathy. This experience sparked her lasting passion for providing comprehensive medical eye care.

As a Key Opinion Leader (KOL) for Labtician, Dr. Jessica also educates and trains clinicians on ocular surface disease, eyelid hygiene, and Meibomian Gland Dysfunction (MGD) management.

Outside the clinic, Dr. Jessica enjoys hiking the trails around Calgary, baking, and learning new languages. Her patients often say her calm, thorough approach makes complex conditions feel manageable.

Whether you’re booking for yourself or your family, Dr. Jessica is accepting new patients of all ages and is happy to provide care in English or Cantonese.

Areas of Special Interest

Myopia Management & Orthokeratology

Dr. Jessica holds an International Academy Certification in Myopia Management and is an elite member of the American Academy of Orthokeratology and Myopia Control. She is one of Calgary’s experienced practitioners in evidence-based myopia management, working closely with families to create personalized treatment plans that help slow myopia progression and protect long-term eye health using Ortho-K, MiSight® daily contact lenses, low-dose atropine therapy, or specialized spectacle lenses.

Dry Eye Disease

Dr. Jessica is passionate about helping patients reclaim their comfort and quality of life from dry eye disease. Taking on a multifaceted approach that combines the latest diagnostic technology and in-office treatments alongside personalized at-home therapy and ocular nutrition guidance, she understands that dry eye is a complex, chronic condition and is committed to getting to the root cause for every patient.

Specialty Contact Lenses

Dr. Jessica is well versed in fitting specialty contact lenses for patients whose vision needs go beyond what standard lenses can offer and her toolkit includes scleral, hybrid, rigid gas permeable (RGP), orthokeratology, and multifocal contact lenses, with each lens carefully chosen to suit the patient’s vision, lifestyle, and overall eye health.

Keratoconus & Complex Corneal Care

Keratoconus and other corneal irregularities are among Dr. Jessica’s areas of clinical interest. Using advanced corneal topography and imaging, she monitors disease progression and provides individualized treatment plans, including custom specialty contact lenses such as scleral and hybrid lenses, to maximize vision, comfort, and long-term ocular health. She also manages patients with post-surgical corneas and other complex or irregular corneal conditions where specialty lenses are often the only option for achieving comfortable, high-quality vision.
Book Appointment Page

Areas We Serve

phone Call NowBook Now

Advanced Myopia Control for Children

Recent randomized controlled clinical trial results presented at the ARVO 2026 Annual Meeting showed promising results for children aged 4–12. Among the 196 children who completed the study, those wearing MiYOSMART iQ showed no average myopia progression after 12 months. The study also found that excessive axial eye growth was reduced to levels below or comparable to those seen in children without refractive errors.

Designed to Help Control Myopia Progression

Myopia, commonly known as short-sightedness, can progress during childhood as the eye grows excessively. Managing myopia earlier in life may help reduce the impact of continued progression and the associated risks of high myopia later in life.

MiYOSMART iQ builds on the established D.I.M.S. Technology used in MiYOSMART lenses and introduces a Triple Enhanced Design (TED). This design incorporates three key enhancements:

  1. Defocus Segments Closer to the Center: The segments are positioned closer to the geometric center of the lens to provide continued exposure to myopic defocus across the near-peripheral retina.
  2. Higher Defocus Power: The lens provides a stronger myopic defocus signal intended to support myopia control.
  3. Extended Treatment Zone: A larger treatment area provides broader coverage of the child’s peripheral visual field, including when larger frames are used.

Clinical Results Across Different Age Groups

The clinical trial included children between 4 and 12 years of age, with results demonstrating myopia-control efficacy across the age groups studied.

For children aged 4–6 years, MiYOSMART iQ demonstrated 65% efficacy in spherical equivalent refractive error (SER) and 44% efficacy in axial length over 12 months. For children aged 7–12 years, the lens demonstrated over 100% efficacy in SER and 94% efficacy in axial length during the same period.

The study also reported a high level of compliance with daily, all-day wear among children across the age groups studied.

Built on Established D.I.M.S. Technology

MiYOSMART iQ represents an evolution of MiYOSMART, a myopia-control lens technology backed by more than 100 peer-reviewed scientific publications. The updated lens design builds on research into how the eye responds to myopic defocus and focuses on delivering a stronger and more consistently positioned defocus signal.

Since its launch in 2018, more than 15 million MiYOSMART spectacle lenses have been purchased by parents across more than 50 countries worldwide.

Supporting Earlier Myopia Management

The clinical findings for MiYOSMART iQ include children as young as four years old, representing an important development in spectacle-lens-based myopia control. Early-onset myopia can progress during a critical period of childhood eye development, making appropriate management an important consideration for children with progressive myopia. MiYOSMART iQ provides an advanced spectacle-lens option for children who require myopia management. An eye care professional can assess your child’s vision and determine whether this type of lens is appropriate for their individual needs.
587-317-2134